Novartis CAR-T deaths raise questions over acceptable autoimmune risk

Many researchers believe cancer cell therapies called CAR-Ts could shift the treatment paradigm for patients with autoimmune disease. But three recently disclosed deaths in Novartis’ clinical trials serve as a stark reminder that the modality ...